Xing Shan, Kan Jun, Su Aishan, Liu Qiao-Dan, Wang Kailin, Cai Xiuyu, Dong Jun
Department of Laboratory, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, P. R. China.
Department of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
Aging (Albany NY). 2019 Oct 4;11(19):8474-8483. doi: 10.18632/aging.102333.
We aimed to characterize the expression of major facilitator superfamily domain-containing protein 2A (MFSD2A) in hepatocellular carcinoma (HCC) patients and analyze its prognostic value.
Immunohistochemistry revealed that low expression of MFSD2A was present in 37 of 79 cases (46.84%), which was significantly correlated with poor histological differentiation ( = 0.012). The plasma MFSD2A level in HCC patients was significantly lower than in healthy controls ( = 0.0079) and controls with chronic hepatitis B virus (HBV) infection ( = 0.0430). Moreover, patients with lower MFSD2A expression had shorter survival than higher expression ( = 0.021). Multivariate analysis revealed that MFSD2A was an independent prognostic predictor for HCC patients ( = 0.027).
The current study indicate MFSD2A may be an optimal diagnostic and prognostic biomarker for HCC.
First, we examined MFSD2A expression in 24 paired HCC and nontumorous tissues by real-time quantitative PCR (RT-qPCR). Second, the protein levels of MFSD2A in 11 paired HCC and nontumorous tissues were investigated by western blotting (WB). Moreover, MFSD2A protein expression was evaluated by immunohistochemistry in 79 HCC patients. In addition, we detected the plasma level of MFSD2A in HCC patients and healthy individuals and investigated the relationship between MFSD2A expression and clinicopathological parameters or prognosis of HCC patients.
我们旨在描述含主要易化子超家族结构域蛋白2A（MFSD2A）在肝细胞癌（HCC）患者中的表达情况，并分析其预后价值。
免疫组织化学显示，79例患者中有37例（46.84%）存在MFSD2A低表达，这与组织学分化差显著相关（P = 0.012）。HCC患者血浆中的MFSD2A水平显著低于健康对照（P = 0.0079）和慢性乙型肝炎病毒（HBV）感染对照（P = 0.0430）。此外，MFSD2A表达较低的患者生存期短于表达较高的患者（P = 0.021）。多因素分析显示，MFSD2A是HCC患者的独立预后预测指标（P = 0.027）。
本研究表明MFSD2A可能是HCC的一种理想诊断和预后生物标志物。
首先，我们通过实时定量PCR（RT-qPCR）检测了24对HCC和非肿瘤组织中MFSD2A的表达。其次，通过蛋白质印迹法（WB）研究了11对HCC和非肿瘤组织中MFSD2A的蛋白水平。此外，通过免疫组织化学评估了79例HCC患者中MFSD2A的蛋白表达。另外，我们检测了HCC患者和健康个体血浆中MFSD2A的水平，并研究了MFSD2A表达与HCC患者临床病理参数或预后之间的关系。
